DMII
Drugs Made In America Acquisition II Corp. (NASDAQ)
Financial Services — Shell Companies
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
None
$10.09
+$0.01 (+0.10%)
Sign in to add DMII to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $641.46M |
| P/E Ratio (TTM) | 71.93 |
| Forward P/E | - |
| EPS (TTM) | $0.14 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 43.7 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.10 |
| 52-Week Low | $9.86 |
| 50-Day Avg | $10.05 |
| 200-Day Avg | $9.99 |
| Avg Volume | 126.9K |
| Volume | 996 |
Performance Analysis
NEUTRALDMII presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($10.10), which may indicate limited upside.
~
RSI at 43.7 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
-
P/E of 71.9 is elevated — the market expects high growth or it may be overvalued.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report